CoChat

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

Open access
Kentsis, Alex, Reed, Casie, Rice, Kim L, Sanda, Takaomi, Rodig, Scott J, Tholouli, Eleni, Christie, Amanda, Valk, Peter J M, Delwel, Ruud, Ngo, Vu, Kutok, Jeffery L, Dahlberg, Suzanne E, Moreau, Lisa A, Byers, Richard J, Christensen, James G, Woude, George Vande, Licht, Jonathan D, Kung, Andrew L, Staudt, Louis M, Look, A Thomas · 2012 · Nature Medicine
Cited by 179

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Although the treatment of acute myeloid leukemia (AML) has improved substantially in the past three decades, more than half of all patients develop disease that is refractory to intensive chemotherapy. Functional genomics approaches offer a means to discover specific molecules mediating the aberrant growth and survival of cancer cells. Thus, using a loss-of-function RNA interference genomic screen, we identified the aberrant expression of hepatocyte growth factor (HGF) as a crucial element in AML pathogenesis. We found HGF expression leading to autocrine activation of its receptor tyrosine kinase, MET, in nearly half of the AML cell lines and clinical samples we studied. Genetic depletion of HGF or MET potently inhibited the growth and survival of HGF-expressing AML cells. However, leukemic cells treated with the specific MET kinase inhibitor crizotinib developed resistance resulting from compensatory upregulation of HGF expression, leading to the restoration of MET signaling. In cases of AML where MET is coactivated with other tyrosine kinases, such as fibroblast growth factor receptor 1 (FGFR1), concomitant inhibition of FGFR1 and MET blocked this compensatory HGF upregulation, resulting in sustained logarithmic cell killing both in vitro and in xenograft models in vivo. Our results show a widespread dependence of AML cells on autocrine activation of MET, as well as the key role of compensatory upregulation of HGF expression in maintaining leukemogenic signaling by this receptor. We anticipate that these findings will lead to the design of additional strategies to block adaptive cellular responses that drive compensatory ligand expression as an essential component of the targeted inhibition of oncogenic receptors in human cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.2819

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 179

Metadata

Authors
Kentsis, A., Reed, C., Rice, K. L., Sanda, T., Rodig, S. J., Tholouli, E., Christie, A., Valk, P. J. M., Delwel, R., Ngo, V., Kutok, J. L., Dahlberg, S. E., Moreau, L. A., Byers, R. J., Christensen, J. G., Woude, G. V., Licht, J. D., Kung, A. L., Staudt, L. M., & Look, A. T.
Venue
Nature Medicine
Published
2012-06-10
Volume
18
Issue
7
Pages
1118-1122
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2089471687
Cited by
179
References
1
FWCI
10.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. https://app.cochat.ai/papers/10.1038/nm.2819
The paper
Kentsis, A., Reed, C., Rice, K. L., Sanda, T., Rodig, S. J., Tholouli, E., Christie, A., Valk, P. J. M., Delwel, R., Ngo, V., Kutok, J. L., Dahlberg, S. E., Moreau, L. A., Byers, R. J., Christensen, J. G., Woude, G. V., Licht, J. D., Kung, A. L., Staudt, L. M., & Look, A. T. (2012). Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nature Medicine. https://doi.org/10.1038/nm.2819

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.